Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Palbociclib vs Ribociclib as Second Line Treatment in Metastatic Breast Cancer
NCT05670054Phase 3Unknown
- Sponsor
- Mansoura University
- Start
- Mar 2022
- Primary completion
- Oct 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial in breast cancer comparing Palbociclib + Fulvestrant with Ribociclib + Fulvestrant (2 arms). Primary endpoints: Objective Response Rate at 6 months, Incidence and grade of toxicity at 6 months and 1 more. Status: unknown.
02
Drugs
palbociclibribociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05670054.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05670054.